BioPharma Dive October 17, 2024
Kristin Jensen

The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.

Dive Brief:

  • Lexicon Pharmaceuticals is selling rights to its only marketed drug outside of the U.S. and Europe amid a restructuring and push to expand into Type 1 diabetes.
  • Viatris has agreed to pay $25 million upfront for rights to sotagliflozin, Lexicon said Wednesday. Lexicon will also be eligible for royalties and payments for meeting certain regulatory and sales milestones. The milestone payments could add up to about $200 million, Jefferies analyst Andrew Tsai wrote in a note to clients.
  • Lexicon currently sells the drug under the brand name Inpefa to reduce the risk of...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Related Articles:
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry
GLP-1 drug coverage for obesity making inroads with large employers: Mercer

Share This Article